Novo Nordisk and Dewpoint Therapeutics have joined forces in a groundbreaking effort to harness the power of Dewpoint’s biomolecular condensates discovery platform to develop treatments for insulin resistance and diabetic complications. This collaboration holds the promise of revolutionizing the fight against these debilitating conditions.
Novo Nordisk and Dewpoint have joined forces to harness the power of AI and discovery to create potential small molecule drugs to tackle multiple condensate targets. With Novo Nordisk’s expertise in diabetes and Dewpoint’s cutting-edge AI platform, the two companies are poised to make a major impact in the fight against diabetes and other related diseases.
Novo Nordisk is strengthening its already robust diabetes pipeline with an exciting new alliance. Their current diabetes products, such as Tresiba (insulin degludec) and Rybelsus (semaglutide), are already helping people manage their diabetes, and this new alliance will help to even further advance the care and treatment of diabetes.
Dewpoint’s revolutionary discovery platform is poised to revolutionize drug discovery with its ability to identify modulators of biomolecular candidates. According to a November 2022 article in Nature Reviews Drug Discovery, the team at Dewpoint believes that biomolecular condensates will be game-changers in the field of drug discovery. With this powerful new tool, researchers are well-positioned to make breakthroughs in the search for new treatments.
In a groundbreaking breakthrough, scientists from Dewpoint have proposed a revolutionary framework for how a better understanding of condensate biology can be leveraged in the drug discovery process across therapeutic areas.
This new framework, described in a recently published article, is the first of its kind to provide a comprehensive and cohesive logic for how this knowledge can be applied. According to Isaac Klein, CSO of Dewpoint and corresponding author of the article, this could be a game-changer in terms of how drug discovery is approached.
In February 2022, Dewpoint secured a staggering $150 million in a Series C financing round to turbocharge its programs, elevate its biology and AI-driven data science platforms, and amplify its research infrastructure and capabilities. This exciting development signals a major step forward in the company’s long-term vision.
Dewpoint is in for a big payday! The Boston-based biotech has just entered into a lucrative partnership that could net them a whopping $55 million in near-term payments, including an upfront fee, research funding, and potential research milestones for two programs.
Dewpoint’s impressive list of partners is growing ever larger with the addition of their latest deal. Previous collaborators include the likes of Bayer, Merck and Pfizer, demonstrating their commitment to delivering top-tier products and services.
On top of that, they could also receive up to $690 million in clinical, commercial, sales milestones, and royalties for two products already on the market. Talk about a sweet deal!
Novo Nordisk has the potential to unlock further rewards with the pursuit of other modalities for the condensates. Should they succeed, Dewpoint stands to gain an additional $107.5 million in total milestones per product. With this in mind, the company is likely to be motivated to explore new avenues of success.
Dewpoint’s impressive list of partners is growing ever larger with the addition of their latest deal. Previous collaborators include the likes of Bayer, Merck and Pfizer, demonstrating their commitment to delivering top-tier products and services.